Real-life experience using topical chlormethine gel in the treatment of stage IA to IVA2 mycosis fungoides: a single-centre experience of 66 patients
Topical chlormethine gel is an antineoplastic alkylating agent licensed in the UK as Ledaga in August 2021 for early-stage mycosis fungoides (IA, IB and IIA). We present real-life data on the use of topical chlormethine gel in our cohort of 66 patients with mycosis fungoides and demonstrate that it is an effective long-term skin-directed therapy, which can be used either as a single agent or in combination with systemic therapy.
Authors
- Van Sim (ORCID: https://orcid.org/0009-0005-7116-906X)
- Stephen Morris (ORCID: https://orcid.org/0000-0002-7505-5327)
- Mary Wain (ORCID: https://orcid.org/0009-0008-0880-2792)
- Farrah Bakr (ORCID: https://orcid.org/0000-0002-2753-8586)
- Bjorn Thomas (ORCID: https://orcid.org/0000-0002-1815-3502)
- Sean Whittaker (ORCID: https://orcid.org/0000-0003-0972-2600)
- Claire Lusted
- Rita Entsua Mensah
- Fiona Child
Institutions
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Institute of Dermatology (TH)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1093/ced/llaf265
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00